Arena hopes lower concentration of obesity drug in human brain will reassure FDA
This article was originally published in Scrip
Executive Summary
Arena Pharmaceuticals and commercial partner Eisai Co said that a small nine-patient trial in obese volunteers of the experimental obesity drug lorcaserin (Lorqess) shows that the drug appears to concentrate less in the brains of humans than it does in rats. The partners hope that the finding may ease concerns of the US FDA that there is human relevance of the observation of lorcaserin-emergent brain astrocytoma in male rats.